Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

BACKGROUND: CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) are approved for the treatment of ER+ advanced breast cancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. We previously reported a novel therapeutic agent, ERX-11, that binds to the estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Viswanadhapalli, Suryavathi, Ma, Shihong, Sareddy, Gangadhara Reddy, Lee, Tae-Kyung, Li, Mengxing, Gilbreath, Collin, Liu, Xihui, Luo, Yiliao, Pratap, Uday P., Zhou, Mei, Blatt, Eliot B., Kassees, Kara, Arteaga, Carlos, Alluri, Prasanna, Rao, Manjeet, Weintraub, Susan T., Tekmal, Rajeshwar Rao, Ahn, Jung-Mo, Raj, Ganesh V., Vadlamudi, Ratna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933697/
https://www.ncbi.nlm.nih.gov/pubmed/31878959
http://dx.doi.org/10.1186/s13058-019-1227-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933697/
https://www.ncbi.nlm.nih.gov/pubmed/31878959
http://dx.doi.org/10.1186/s13058-019-1227-8

Ejemplares similares